Loading company
Keep exploring
The themes Immix Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now A
How it makes money
- No product revenue
Competes with
What it sells1
NXC-201
A treatment made from a patient’s own immune cells, altered to recognize BCMA on diseased cells. It is being studied mainly for relapsed or treatment-resistant AL amyloidosis.
What it stands on, and what could break it
What the business leans on
- 1Immix depends on raising outside capital and receiving grant reimbursements to pay for research and clinical trials; it has no product sales.
- 2It relies on outside contract manufacturers to make its treatment candidates for studies and any future commercial use.
- 3It relies on a license from Hadasit and BIRAD for intellectual property used in NXC-201, and owes payments under that agreement.
- 4Progress depends on enrolling patients, completing clinical studies, and obtaining regulatory approval before any treatment can be sold.
What could go wrong
- 1Clinical studies may fail to show that NXC-201 is safe and effective, or regulators may decide the results are not enough to approve it.
- 2Immix has recurring losses and no product revenue, so it must secure further funding; if it cannot, it may have to delay, reduce, or stop development work.
- 3Reliance on outside manufacturers and licensed intellectual property could delay or disrupt development if suppliers fail to meet requirements or license rights are lost.
About Immix Biopharma, Inc.
Immix is developing chimeric antigen receptor T-cell (CAR-T) treatments, which use a patient’s own immune cells, changed to recognize and attack diseased cells. Its main candidate, NXC-201, is designed to target B-cell maturation antigen (BCMA) on cells involved in light-chain (AL) amyloidosis. Its U.S. study of NXC-201 had enrolled 45 patients by June 30, 2026 (high confidence). Immix has no approved medicines for sale and has not generated revenue from product sales.
- Head office
- Los Angeles, California
- Founded
- 2012
- Employees
- 21 (March 20, 2026, high)
- Listed on
- Nasdaq Capital Market
- Financial year ends
- December 31
Built from Immix Biopharma, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
